C
AMBRIDGE, Mass.--Millennium Pharmaceuticals announced that it will acquire the remaining shares of its Millennium Predictive Medicine subsidiary that it does not already own, making it a wholly owned subsidiary. The company said that the transaction, a stock-for-stock exchange, will align more closely Millennium’s therapeutic and predictive medicine discovery and development efforts.
The predictive medicine company develops what it calls Diagnomic and pharmacogenomic products and services. Diagnomics are molecular diagnostics that describe a patient’s current medical condition and provide prognostic and therapeutic information. Pharmacogenomic tests determine a patient’s response to a specific therapeutic based on their genetic information.
